Nimustine (INN ) is a nitrosourea alkylating agent.[1]
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
Routes of administration | Intravenous |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.050.744 |
Chemical and physical data | |
Formula | C9H13ClN6O2 |
Molar mass | 272.69 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
It is used to treat malignant brain tumors and has proven to be rather effective.[2][3]
References
edit- ^ "NCI Drug Dictionary". National Cancer Institute. Retrieved 2019-03-17.
- ^ CHEBI:75270 - nimustine
- ^ Endo T, Inoue T, Sugiyama S, Saito R, Tominaga T (April 2020). "Regression of Recurrent Spinal Cord High-Grade Glioma After Convection-Enhanced Delivery of Nimustine Hydrochloride: Case Reports and Literature Review". Operative Neurosurgery (Hagerstown, Md.). 18 (4): 451–459. doi:10.1093/ons/opz172. PMID 31414134.